Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

More confirmation for ConfirmMDx
10-11-2017
SHARING OPTIONS:

IRVINE, Calif. & HERSTAL, Belgium—A recent study by MDxHealth SA has further validated ConfirmMDx for Prostate Cancer and demonstrated that the assay can provide more information on patients’ risk for aggressive prostate cancer. The study enrolled 102 men, each of which underwent a standard 12-core diagnostic biopsy, with the ConfirmMDx test then applied to the tissue cores. Twenty men had cancer-negative biopsies, 46 had low-grade cancer (Gleason Score 6, GS6, or less) and 36 had high-grade disease (GS7 or greater). Those with high-grade disease had significantly higher ConfirmMDx risk scores as well as high methylation intensities.
 
“The ConfirmMDx clinical model is a powerful molecular tool that can help compensate for prostate biopsy limitations and provide a more accurate risk assessment without conducting further invasive procedures. In addition to ConfirmMDx identifying false-negative biopsy results, the risk score can more accurately predict a patient’s cancer grade upon repeat biopsy,” said Dr. Sandra Gaston, a professor in the Department of Pathology and Laboratory Medicine at Tufts University School of Medicine.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.